10.13.11
YTD Revenues: 31.5 billion (-13%)
Comments: Group sales were down -12%, excluding Tamiflu. Pharmaceutical sales were 24.4 billion (-14%). Herceptin sales were up +8% and MabThera/Rituxan, up +7%. Lucentis sales were up 26%. Actemra sales jumped +86%. Professional Diagnostics business revenues were up 9%. Foreign exchange negatively impacted results by -13% due to appreciation of the Swiss franc.
All numbers reported in CHF
Comments: Group sales were down -12%, excluding Tamiflu. Pharmaceutical sales were 24.4 billion (-14%). Herceptin sales were up +8% and MabThera/Rituxan, up +7%. Lucentis sales were up 26%. Actemra sales jumped +86%. Professional Diagnostics business revenues were up 9%. Foreign exchange negatively impacted results by -13% due to appreciation of the Swiss franc.
All numbers reported in CHF